On Wednesday, Lyra Therapeutics earned a positive adjustment to its Relative Strength (RS) Rating, from 87 to 93.
How To Use Stock Charts To Stay Profitable And Protected
This exclusive rating from Investor's Business Daily tracks market leadership with a 1 (worst) to 99 (best) score. The grade shows how a stock's price behavior over the trailing 52 weeks compares to all the other stocks in our database.
Over 100 years of market history reveals that the market's biggest winners tend to have an RS Rating north of 80 as they begin their biggest climbs.
While Lyra Therapeutics is not near an ideal buying range right now, see if it is able to form and break out from a proper base.
Lyra Therapeutics reported 0% EPS growth last quarter, while sales growth came in at -66%.
Lyra Therapeutics holds the No. 250 rank among its peers in the Medical-Biomed/Biotech industry group. Exelixis, TG Therapeutics and ACADIA Pharmaceuticals are among the top 5 highly rated stocks within the group.
This article was created automatically with Stats Perform's Wordsmith software using data and article templates supplied by Investor's Business Daily. An IBD journalist may have edited the article.
RELATED:
Biotech And Pharmaceutical Industry And Stock News
Stocks With Rising Relative Strength Ratings
Why Should You Use IBD's Relative Strength Rating?
How Relative Strength Line Can Help You Judge A Stock
Ready To Grow Your Investing Skills? Join An IBD Meetup Group!
